NASDAQ:GPCR Structure Therapeutics Q1 2025 Earnings Report $36.91 +0.10 (+0.27%) Closing price 09/22/2026 04:00 PM EasternExtended Trading$37.12 +0.21 (+0.57%) As of 08:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Structure Therapeutics EPS ResultsActual EPS-$0.27Consensus EPS -$0.24Beat/MissMissed by -$0.03One Year Ago EPSN/AStructure Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AStructure Therapeutics Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time4:00PM ETUpcoming EarningsStructure Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Structure Therapeutics Earnings HeadlinesStructure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In FocusSeptember 22 at 9:22 AM | finance.yahoo.comStructure Therapeutics Inc ADR (GPCR)September 19, 2026 | za.investing.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 23 at 1:00 AM | Paradigm Press (Ad)Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comStructure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?September 10, 2026 | insidermonkey.comStructure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - SlideshowSeptember 9, 2026 | seekingalpha.comSee More Structure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email. Email Address About Structure TherapeuticsStructure Therapeutics (NASDAQ:GPCR) Inc. is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions. Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes. Unlike injectable GLP-1 therapies, the program is designed to provide an oral treatment option. Structure Therapeutics has also described additional discovery and development programs targeting other GPCRs associated with cardiometabolic and pulmonary diseases. The company conducts research and development activities in the United States and China and was established to advance structure-based approaches to drug discovery. Structure Therapeutics is led by Raymond Stevens, Ph.D., a co-founder and experienced drug-discovery scientist who serves as chief executive officer.View Structure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureNucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
